XTalks

SEPTEMBER 17, 2020

The company has agreed to stop production until it takes remedial action and complies with the Federal Food, Drug, and Cosmetic Act. Related: FDA Announces Slow Phase-Out of Certain PFAS Chemicals Used in Food Packaging.

Production 98

Production Contamination Cosmetics Bacteria 98

The Pharma Data

MARCH 29, 2022

an animal food manufacturing company of Carney’s Point, New Jersey, has agreed to stop selling, manufacturing and distributing raw pet food and come into compliance with the Federal Food, Drug, and Cosmetic Act (FD&C Act). Food and Drug Administration (FDA) announced today that Bravo Packing, Inc., Source link: [link].

Manufacturing 52

Manufacturing Contamination Cosmetics Regulation 52

The Pharma Data

FEBRUARY 18, 2022

Cronobacter bacteria can cause severe, life-threatening infections (sepsis) or meningitis (an inflammation of the membranes that protect the brain and spine). Salmonella are a group of bacteria that can cause gastrointestinal illness and fever called salmonellosis. Source link: [link].

Production 40

Production Bacteria Containment Cosmetics 40

XTalks

NOVEMBER 28, 2023

Unpasteurized Milk Unpasteurized milk , also known as raw milk, is a significant health risk due to its potential to harbor dangerous bacteria. Under the provisions of the 1938 Food, Drug, and Cosmetic Act, Kinder Surprise eggs are classified as “adulterated food,” rendering their importation and sale illegal.

Sales 52

Sales Regulation Containment Production 52

The Pharma Data

DECEMBER 13, 2020

The FDA also assessed the risk of the IGA to promote the emergence or selection of antimicrobial-resistant bacteria of human health concern in or on GalSafe pigs. Additionally, no animal safety concerns were noted for GalSafe pigs beyond those that would be expected in well-managed, commercial swine operations.

FDA Approval 52

FDA Approval Genome Genomics Production 52

XTalks

AUGUST 2, 2023

2) Botox Therapeutic/Cosmetic Botox, or botulinum neurotoxin, is a neurotoxic protein produced by the Clostridium botulinum bacteria. The list price of a four-week supply of Humira was reported to be $6,922.62 in January 2023, according to the manufacturer. AbbVie’s total global revenue for Humira was $21.24 billion in 2022.

Sales 98

Sales Manufacturing FDA Approval Life Science 98